APAAACI TV Special COVID-19 Report; Prof Giorgio Walter Canonica. COVID-19 and Asthma. June 2020

Anaphylaxis to three humanized antibodies for severe asthma: a case study

• Case report
• Open Access
• 
  

Allergy, Asthma & Clinical Immunology

• Koichi Jingo, 
• Norihiro Harada, 
• Toshihiko Nishioki, 
• Masahiro Torasawa, 
• Tomoko Yamada, 
• Tetsuhiko Asao, 
• Haruhi Takagi, 
• Tomohito Takeshige, 
• Jun Ito & 
• Kazuhisa Takahashi 

Allergy, Asthma & Clinical Immunology volume 16, Article number: 46 (2020) 

• details

Abstract

Background

Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare.

Digital transformation of health and care to sustain Planetary Health: The MASK proof-of-concept for airway diseases—POLLAR symposium under the auspices of Finland’s Presidency of the EU, 2019 and MACVIA-France, Global Alliance against Chronic Respiratory Diseases (GARD, WH0) demonstration project, Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing

Clinical and Translational Allergy

Jean Bousquet, 

Josep M. Anto, 

[…]

Daniel Laune 

Clinical and Translational Allergy volume 10, Article number: 24 (2020) 

• details

Abstract

In December 2019, a conference entitled “Europe That Protects: Safeguarding Our Planet, Safeguarding Our Health” was held in Helsinki. It was co-organized by the Finnish Institute for Health and Welfare, the Finnish Environment Institute and the European Commission, under the auspices of Finland’s Presidency of the EU. As a side event, a symposium organized as the final POLLAR (Impact of air POLLution on Asthma and Rhinitis) meeting explored the digital transformation of health and care to sustain planetary health in airway diseases.

The Finnish Allergy Programme collaborates with MASK (Mobile Airways Sentinel NetworK) and can be considered as a proof-of-concept to impact Planetary Health. The Good Practice of DG Santé (The Directorate-General for Health and Food Safety) on digitally-enabled, patient-centred care pathways is in line with the objectives of the Finnish Allergy Programme.

World Allergy Week 2020 - 28 June - 4 July 2020

World Allergy Week 2020

The World Allergy Organization is proud to announce that World Allergy Week 2020 will occur 28 June - 4 July 2020 and will focus on the theme of "Allergy care does not stop with COVID-19."

Each year, the World Allergy Organization (WAO) addresses a different topic that has a need for greater awareness. To accomplish this, WAO provides physicians and the general public with a webinar, infographic, and additional information to educate and spread awareness on the topic. Additional details on these items will be coming soon.

Join us for a World Allergy Week webinar on 2 July 2020 at 8:00 am EDT. Time zone converter

COVID-19 and Allergic Diseases

Introduction
Motohiro Ebisawa, Japan

International perspective on the COVID-19 pandemic and allergic diseases
Gary Wing Kin Wong, Hong Kong

Psychological effects of the COVID-19 pandemic on allergic patients
Sandra González Díaz, Mexico

Effect of COVID-19 on the treatment of allergic patients
Bryan Martin, USA

How does the COVID-19 pandemic affect our asthma patients?
Mário Morais-Almeida, Portugal

Pediatric issues related to allergy and COVID-19
Elham Hossny, Egypt

Registration information coming soon.

Hoy Jueves 18/06/2020 3 webinars casi simultáneos

Hoy 3 webinars casi simultáneos. Elija en cuál participar y cuáles reservar para verlos tranquilos el fin de semana (seguramente serán grabados y distribuidos los links por los organizadores:

https://event.webinarjam.com/register/663/yy1k4cq58

https://makmedia1.clickmeeting.com/eurofarma-rinitis

Que los disfruten!

Viral infections and wheezing–asthma inception in childhood: is there a role for immunomodulation by oral bacterial lysates?

• Review
• Open Acces

• Giovanni A. Rossi, 
• Petr Pohunek, 
• Wojciech Feleszko, 
• Stefania Ballarini & 
• Andrew A. Colin 

Clinical and Translational Allergy volume 10, Article number: 17 (2020) 

• details

Abstract

Severe and recurrent infections of the respiratory tract in early childhood constitute major risk factors for the development of bronchial hyper-responsiveness and obstructive respiratory diseases in later life. In the first years of life, the vast majority of respiratory tract infections (RTI) leading to wheezing and asthma are of a viral origin and severity and recurrence are the consequence of a greater exposure to infectious agents in a period when the immune system is still relatively immature.

WAO "Special Session - in View of WISC 2020: Allergy and COVID"

WAO "Special Session - in View of WISC 2020: Allergy and COVID" 

Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis

Melanie C. Dispenza,1 Rebecca A. Krier-Burris,2 Krishan D. Chhiba,2 Bradley J. Undem,1 Piper A. Robida,2 and Bruce S. Bochner2 

Abstract

No known therapies can prevent anaphylaxis. Bruton’s tyrosine kinase (BTK) is an enzyme thought to be essential for high-affinity IgE receptor (FcεRI) signaling in human cells. We tested the hypothesis that FDA-approved BTK inhibitors (BTKi’s) would prevent IgE-mediated responses including anaphylaxis. We showed that irreversible BTKi’s broadly prevented IgE-mediated degranulation and cytokine production in primary human mast cells and blocked allergen-induced contraction of isolated human bronchi.